RxDoctor Payments Data

Sharad Soni, MD

Internal Medicine · Ozone Park, NYNPI 1295701357

Payments from drug & device makers

$250in general payments, 2019–2025

Across 8 payments — averaging $31.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$121
  • Merck$40
  • Acadia Pharmaceuticals Inc$35
  • Neurocrine Biosciences, Inc.$25
  • GSK$15
  • Novartis$14

What the payments were for

  • Food & beverage$250100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$250 in reported general payments places this provider in the 50th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$177,917
Medicare patients
203
Services billed
1,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban212$84,321
RybelsusSemaglutide25$44,994
JanuviaSitagliptin Phosphate50$40,324
Glatiramer Acetate13$38,610
XareltoRivaroxaban76$38,463
Clemastine Fumarate12$34,724
OzempicSemaglutide33$32,349
TrulicityDulaglutide30$31,262
JardianceEmpagliflozin15$20,672
MultaqDronedarone Hcl38$17,871
JanumetSitagliptin Phos/Metformin Hcl16$15,110
LinzessLinaclotide23$14,683
Lacosamide45$12,750
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,593
Breo ElliptaFluticasone/Vilanterol12$12,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$40$55,43466 claims
Johnson & JohnsonXarelto$121$38,46376 claims
GSKTrelegy Ellipta, Breo Ellipta$15$25,04226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Ozone Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →